Update on new aspects of the renin-angiotensin system in liver disease: Clinical implications and new therapeutic options

Clinical Science

Volumn 123, Issue 4, 2012, Pages 225-239

  Grace, Josephine A ^a,b   Herath, Chandana B ^a   Mak, Kai Yan ^a   Burrell, Louise M ^a   Angus, Peter W ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Cirrhosis; Liver fibrosis; Portal hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERFERON; LOSARTAN; METFORMIN; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NITRIC OXIDE; PERINDOPRIL; PLACEBO; ROSIGLITAZONE; TELMISARTAN; URSODEOXYCHOLIC ACID; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II;

ANGIOTENSIN BLOOD LEVEL; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEPATIC VEIN; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPLANCHNIC BLOOD FLOW; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; GENETICS; LIVER; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SPLANCHNIC CIRCULATION; VASODILATION;

EID: 84862334206     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120030     Document Type: Review

References (162)

1. World Health Organization (2008). The global burden of disease: 2004 update. World Health Organization, Geneva
2. Kochanek, K. D., Xu, J., Murphy, S. L., Miniño, A. M. and Kung, H.-C. (2011) Deaths: preliminary data for 2009. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System 54, 1-51
3. Dickstein, K. and Kjekshus, J. (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Lancet 360, 752-760
4. Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. and Hollenberg, N. K. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446
5. Skipworth, J. R. A., Szabadkai, G., Olde Damink, S.W. M., Leung, P. S., Humphries, S. E. and Montgomery, H. E. (2011) Pancreatic renin-angiotensin systems in health and disease. Aliment. Pharmacol. Ther. 34, 840-852
6. Lubel, J. S., Herath, C. B., Burrell, L. M. and Angus, P.W. (2008) Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J. Gastroenterol. Hepatol. 23, 1327-1338
7. Paul, M., Poyan Mehr, A. and Kreutz, R. (2006) Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747-803
8. Ayers, C. R. (1967) Plasma renin activity and renin-substrate concentration in patients with liver disease. Circ. Res. 20, 594-598
9. Epstein, M., Levinson, R. and Sancho, J. (1977) Characterization of the renin aldosterone system in decompensated cirrhosis. Circ. Res. 41, 818-829
10. Herath, C. B., Warner, F. J., Lubel, J. S., Dean, R. G., Jia, Z., Lew, R. A., Smith, A. I., Burrell, L. M. and Angus, P. W. (2007) Upregulation of hepatic angiotensinconverting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J. Hepatol. 47, 387-395
11. Paizis, G., Cooper, M. E., Schembri, J. M., Tikellis, C., Burrell, L. M. and Angus, P. W. (2002) Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123, 1667-1676
12. Paizis, G., Tikellis, C., Cooper, M. E., Schembri, J. M., Lew, R. A., Smith, A. I., Shaw, T., Warner, F. J., Zuilli, A., Burrell, L. M. and Angus, P. W. (2005) Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 54, 1790-1796
13. Page, I. H. and Bumpus, F. M. (1961) Angiotensin. Physiol. Rev. 41, 331-390
14. Braun-Menendez, E. and Page, I. H. (1958) Suggested revision of nomenclature - angiotensin. Science 127, 242
15. Suzuki, Y., Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V. and Egido, J. (2003) Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35, 881-900
16. Ruiz-Ortega, M., Lorenzo, O., Suzuki, Y., Ruṕerez, M. and Egido, J. (2001) Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 10, 321-329
17. Mezzano, S. A., Ruiz-Ortega, M. and Egido, J. (2001) Angiotensin II and renal fibrosis. Hypertension 38, 635-638
18. Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P. and Bernstein, K. E. (1995) Direct stimulation of Jak/STAT pathway by the anglotensin II AT1 receptor. Nature 375, 247-250
19. Kagami, S., Border, W. A., Miller, D. E. and Noble, N. A. (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. 93, 2431-2437
20. Velloso, L. A., Folli, F., Sun, X. J., White, M. F., Saad, M. J. A. and Kahn, C. R. (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. U.S.A. 93, 12490-12495
21. de Kloet, A. D., Krause, E. G. and Woods, S. C. (2010) The renin angiotensin system and the metabolic syndrome. Physiol. Behav. 100, 525-534
22. Nguyen, G. (2011) Renin, (pro)renin and receptor: an update. Clin. Sci. 120, 169-178
23. Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., Da Costa, J., Zhang, L., Pei, Y. et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828
24. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R. et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9
25. Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G. and Turner, A. J. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243
26. Gembardt, F., Sterner-Kock, A., Imboden, H., Spalteholz, M., Reibitz, F., Schultheiss, H. P., Siems, W. E. and Walther, T. (2005) Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26, 1270-1277
27. Warner, F. J., Lew, R. A., Smith, A. I., Lambert, D. W., Hooper, N. M. and Turner, A. J. (2005) Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J. Biol. Chem. 280, 39353-39362
28. Lambert, D.W., Yarski, M., Warner, F. J., Thornhill, P., Parkin, E. T., Smith, A. I., Hooper, N. M. and Turner, A. J. (2005) Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280, 30113-30119
29. Lai, Z.W., Lew, R. A., Yarski, M. A., Mu, F. T., Andrews, R. K. and Smith, A. I. (2009) The identification of a calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2. Endocrinology 150, 2376-2381
30. Lambert, D. W., Clarke, N. E., Hooper, N. M. and Turner, A. J. (2008) Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett. 582, 385-390
31. Guy, J. L., Jackson, R. M., Acharya, K. R., Sturrock, E. D., Hooper, N. M. and Turner, A. J. (2003) Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry (Moscow) 42, 13185-13192
32. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F. et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843
33. Rice, G. I., Thomas, D. A., Grant, P. J., Turner, A. J. and Hooper, N. M. (2004) Evaluation of angiotensinconverting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 383, 45-51
34. Zisman, L. S., Meixell, G. E., Bristow, M. R. and Canver, C. C. (2003) Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108, 1679-1681
35. Santos, R. A., Simoes e Silva, A. C., Maric, C., Silva, D. M., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V., Lopes, M. T., Bader, M. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263
36. Li, P., Chappell, M. C., Ferrario, C. M. and Brosnihan, K. B. (1997) Angiotensin-(1-7) augments bradykinininduced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29, 394-398
37. Lima, C. V., Paula, R. D., Resende, F. L., Khosla, M. C. and Santos, R. A. S. (1997) Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 30, 542-548
38. Oliveira, M. A., Carvalho, M. H., Nigro, D., Passaglia Rde, C. and Fortes, Z. B. (2002) Angiotensin-(1-7) and bradykinin interaction in diabetes mellitus: in vivo study. Peptides 23, 1449-1455
39. Ren, Y., Garvin, J. L. and Carretero, O. A. (2002) Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39, 799-802
40. Sampaio, W. O., Nascimento, A. A. S. and Santos, R. A. S. (2003) Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am. J. Physiol. Heart Circ. Physiol. 284, H1985-H1994
41. Peiro, C., Vallejo, S., Gembardt, F., Azcutia, V., Heringer-Walther, S., Rodriguez-Manas, L., Schultheiss, H. P., Sanchez-Ferrer, C. F. and Walther, T. (2007) Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J. Hypertens. 25, 2421-2425
42. Ferreira, A. J., Santos, R. A. and Almeida, A. P. (2001) Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 38, 665-668
43. Freeman, E. J., Chisolm, G. M., Ferrario, C. M. and Tallant, E. A. (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28, 104-108
44. Tallant, E. A. and Clark, M. A. (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42, 574-579
45. Tallant, E. A., Ferrario, C. M. and Gallagher, P. E. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289, H1560-H1566
46. Heitsch, H., Brovkovych, S., Malinski, T. and Wiemer, G. (2001) Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 37, 72-76
47. Muthalif, M. M., Benter, I. F., Uddin, M. R., Harper, J. L. and Malik, K. U. (1998) Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J. Pharmacol. Exp. Ther. 284, 388-398
48. Walters, P. E., Gaspari, T. A. and Widdop, R. E. (2005) Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45, 960-966
49. Tesanovic, S., Vinh, A., Gaspari, T. A., Casley, D. and Widdop, R. E. (2010) Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler., Thromb., Vasc. Biol. 30, 1606-1613
50. Schrier, R. W., Arroyo, V., Bernardi, M., Epstein, M., Henriksen, J. H. and Rod́es, J. (1988) Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151-1157
51. Bataller, R., Sancho-Bru, P., Gines, P., Lora, J. M., Al-Garawi, A., Sole, M., Colmenero, J., Nicolas, J. M., Jimenez, W., Weich, N. et al. (2003) Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125, 117-125
52. Lubel, J. S., Herath, C. B., Tchongue, J., Grace, J., Jia, Z., Spencer, K., Casley, D., Crowley, P., Sievert, W., Burrell, L. M. and Angus, P. W. (2009) Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin. Sci. 117, 375-386
53. Bataller, R. and Brenner, D. A. (2005) Liver fibrosis. J. Clin. Invest. 115, 209-218
54. Friedman, S. L. (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669
55. Weber, K. T. (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96, 4065-4082
56. Bataller, R., Gines, P., Nicolas, J. M., Gorbig, M. N., Garcia-Ramallo, E., Gasull, X., Bosch, J., Arroyo, V. and Rodes, J. (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118, 1149-1156
57. Bataller, R., Gabele, E., Schoonhoven, R., Morris, T., Lehnert, M., Yang, L., Brenner, D. A. and Rippe, R. A. (2003) Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G642-G651
58. Bataller, R., Schwabe, R. F., Choi, Y. H., Yang, L., Paik, Y. H., Lindquist, J., Qian, T., Schoonhoven, R., Hagedorn, C. H., Lemasters, J. J. and Brenner, D. A. (2003) NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112, 1383-1394
59. Hirose, A., Ono, M., Saibara, T., Nozaki, Y., Masuda, K., Yoshioka, A., Takahashi, M., Akisawa, N., Iwasaki, S., Oben, J. A. and Onishi, S. (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45, 1375-1381
60. Kim, M. Y., Baik, S. K., Park, D. H., Jang, Y. O., Suk, K. T., Yea, C. J., Lee, I. Y., Kim, J.W., Kim, H. S., Kwon, S. O. et al. (2008) Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J. Gastroenterol. 43, 889-896
61. Tuncer, I., Ozbek, H., Ugras, S. and Bayram, I. (2003) Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat: the effect of AT1-R blocker on the hepatic fibrosis. Exp. Toxicol. Pathol. 55, 159-166
62. Ueki, M., Koda, M., Yamamoto, S., Matsunaga, Y. and Murawaki, Y. (2006) Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J. Gastroenterol. 41, 996-1004
63. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H. and Fukui, H. (2001) Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34, 745-750
64. Bataller, R., Gabele, E., Parsons, C. J., Morris, T., Yang, L., Schoonhoven, R., Brenner, D. A. and Rippe, R. A. (2005) Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41, 1046-1055
65. Yang, L., Bataller, R., Dulyx, J., Coffman, T. M., Gines, P., Rippe, R. A. and Brenner, D. A. (2005) Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J. Hepatol. 43, 317-323
66. Kanno, K., Tazuma, S. and Chayama, K. (2003) AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl4. Biochem. Biophys. Res. Commun. 308, 177-183
67. Nabeshima, Y., Tazuma, S., Kanno, K., Hyogo, H., Iwai, M., Horiuchi, M. and Chayama, K. (2006) Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem. Biophys. Res. Commun. 346, 658-664
68. Lubel, J. S., Herath, C. B., Jia, Z., Burrell, L. M. and Angus, P. W. (2007) Angiotensin-(1-7) infusion reduces bile duct proliferation and hepatic fibrosis in the bile duct ligated rat. Hepatology 46, 706A-707A
69. Pereira, R. M., Dos Santos, R. A., Teixeira, M. M., Leite, V. H., Costa, L. P., da Costa Dias, F. L., Barcelos, L. S., Collares, G. B. and Simoes e Silva, A. C. (2007) The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of angiotensin-(1-7). J. Hepatol. 46, 674-681
70. Osterreicher, C. H., Taura, K., De Minicis, S., Seki, E., Penz-Osterreicher, M., Kodama, Y., Kluwe, J., Schuster, M., Oudit, G. Y., Penninger, J. M. and Brenner, D. A. (2009) Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology 50, 929-938
71. Jonsson, J. R., Clouston, A. D., Ando, Y., Kelemen, L. I., Horn, M. J., Adamson, M. D., Purdie, D. M. and Powell, E. E. (2001) Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121, 148-155
72. Kurikawa, N., Suga, M., Kuroda, S., Yamada, K. and Ishikawa, H. (2003) An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 139, 1085-1094
73. Iwata, M., Cowling, R. T., Gurantz, D., Moore, C., Zhang, S., Yuan, J. X. and Greenberg, B. H. (2005) Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol. 289, H2356-H2363
74. Ohishi, T., Saito, H., Tsusaka, K., Toda, K., Inagaki, H., Hamada, Y., Kumagai, N., Atsukawa, K. and Ishii, H. (2001) Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachlorideinduced hepatic fibrosis in rats. Hepatol. Res. 21, 147-158
75. Paizis, G., Gilbert, R. E., Cooper, M. E., Murthi, P., Schembri, J. M., Wu, L. L., Rumble, J. R., Kelly, D. J., Tikellis, C., Cox, A. et al. (2001) Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J. Hepatol. 35, 376-385
76. Ramos, S. G., Montenegro, A. P., Goissis, G. and Rossi, M. A. (1994) Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathol. Int. 44, 655-661
77. Wei, H. S., Li, D. G., Lu, H. M., Zhan, Y. T., Wang, Z. R., Huang, X., Zhang, J., Cheng, J. L. and Xu, Q. F. (2000) Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4. World J. Gastroenterol. 6, 540-545
78. Wei, H. S., Lu, H. M., Li, D. G., Zhan, Y. T., Wang, Z. R., Huang, X., Cheng, J. L. and Xu, Q. F. (2000) The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl4. World J. Gastroenterol. 6, 824-828
79. Yoshiji, H., Yoshii, J., Ikenaka, Y., Noguchi, R., Tsujinoue, H., Nakatani, T., Imazu, H., Yanase, K., Kuriyama, S. and Fukui, H. (2002) Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. 37, 22-30
80. Ramalho, L. N., Ramalho, F. S., Zucoloto, S., Castro-e-Silva Junior, O., Correa, F. M., Elias Junior, J. and Magalhaes, J. F. (2002) Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 49, 1499-1502
81. Ibanez, P., Solis, N., Pizarro, M., Aguayo, G., Duarte, I., Miquel, J. F., Accatino, L. and Arrese, M. (2007) Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22, 846-851
82. Toblli, J. E., Mũoz, M. C., Cao, G., Mella, J., Pereyra, L. and Mastai, R. (2008) ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity 16, 770-776
83. Colmenero, J., Bataller, R., Sancho-Bru, P., Dominguez, M., Moreno, M., Forns, X., Bruguera, M., Arroyo, V., Brenner, D. A. and Gines, P. (2009) Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G726-G734
84. Debernardi-Venon, W., Martini, S., Biasi, F., Vizio, B., Termine, A., Poli, G., Brunello, F., Alessandria, C., Bonardi, R., Saracco, G., Rizzetto, M. and Marzano, A. (2007) AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J. Hepatol. 46, 1026-1033
85. Sookoian, S., Fernandez, M. A. and Castano, G. (2005) Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J. Gastroenterol. 11, 7560-7563
86. Terui, Y., Saito, T., Watanabe, H., Togashi, H. and Kawata, S. (2002) Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36, 1022
87. Yoshiji, H., Noguchi, R. and Fukui, H. (2005) Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C.J. Gastroenterol. 40, 215-216
88. Yoshiji, H., Noguchi, R., Kojima, H., Ikenaka, Y., Kitade, M., Kaji, K., Uemura, M., Yamao, J., Fujimoto, M., Yamazaki, M. et al. (2006) Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J. Gastroenterol. 12, 6786-6791
89. Abu Dayyeh, B. K., Yang, M., Dienstag, J. L. and Chung, R. T. (2011) The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig. Dis. Sci. 56, 564-568
90. Rimola, A., Londono, M. C., Guevara, G., Bruguera, M., Navasa, M., Forns, X., Garcia-Retortillo, M., Garcia-Valdecasas, J. C. and Rodes, J. (2004) Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78, 686-691
91. Cholongitas, E., Vibhakorn, S., Lodato, F. and Burroughs, A. K. (2010) Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation. Liver Int. 30, 334-335
92. Yokohama, S., Tokusashi, Y., Nakamura, K., Tamaki, Y., Okamoto, S., Okada, M., Aso, K., Hasegawa, T., Aoshima, M., Miyokawa, N. et al. (2006) Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J. Gastroenterol. 12, 322-326
93. Yokohama, S., Yoneda, M., Haneda, M., Okamoto, S., Okada, M., Aso, K., Hasegawa, T., Tokusashi, Y., Miyokawa, N. and Nakamura, K. (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40, 1222-1225
94. Torres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A. and Harrison, S. A. (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 54, 1631-1639
95. Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L. and Vancica, L. (2009) Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942-954
96. Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J. M. et al. (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59, 529-538
97. Wysocki, J., Ye, M., Rodriguez, E., Gonzalez-Pacheco, F. R., Barrios, C., Evora, K., Schuster, M., Loibner, H., Brosnihan, K. B., Ferrario, C. M. et al. (2010) Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55, 90-98
98. Schuster, M., Loibner, H., Poglitsch, M., Janzek, E., Stranner, S., Haschke, M. and Kraehenbuehl, S. (2011) Pharmacology of recombinant human angiotensinconverting enzyme 2 in healthy volunteers, Arteriosclerosis, Thrombosis, and Vascular Biology Scientific Sessions. Chicago, P450
99. Benter, I. F., Yousif, M. H., Cojocel, C., Al-Maghrebi, M. and Diz, D. I. (2007) Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H666-H672
100. Ebermann, L., Spillmann, F., Sidiropoulos, M., Escher, F., Heringer-Walther, S., Schultheiss, H. P., Tschope, C. and Walther, T. (2008) The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol. 590, 276-280
101. Ferreira, A. J., Jacoby, B. A., Araujo, C. A., Macedo, F. A., Silva, G. A., Almeida, A. P., Caliari, M. V. and Santos, R. A. (2007) The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 292, H1113-H1119
102. Marques, F. D., Ferreira, A. J., Sinisterra, R. D. M., Jacoby, B. A., Sousa, F. B., Caliari, M. V., Silva, G. A. B., Melo, M. B., Nadu, A. P., Souza, L. E. et al. (2011) An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 57, 477-483
103. Corey, K. E., Shah, N., Misdraji, J., Abu Dayyeh, B. K., Zheng, H., Bhan, A. K. and Chung, R. T. (2009) The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 29, 748-753
104. Kim, M. Y., Baik, S. K., Jang, Y. O., Yea, C. J., Won, C. S., Byun, J.W., Choi, H. and Cho, M.-Y. (2009) The beneficial effect of angiotensin-blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology 50, 1048A-1190A
105. Rockey, D. (1997) The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 25, 2-5
106. Kaneda, K., Ekataksin, W., Sogawa, M., Matsumura, A., Cho, A. and Kawada, N. (1998) Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 27, 735-747
107. Bhathal, P. S. and Grossman, H. J. (1985) Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J. Hepatol. 1, 325-337
108. Herath, C. B., Lubel, J. S., Jia, Z., Velkoska, E., Casley, D., Brown, L., Tikellis, C., Burrell, L. M. and Angus, P.W. (2009) Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G97-G106
109. Herath, C. B., Jia, Z., Burrell, L. M. and Angus, P. W. (2009) Angiotensin-(1-7) attenuates angiotensin II-induced increases in hepatic resistance in cirrhotic rat liver. Hepatology 50, 482A
110. Pagliaro, L., D'Amico, G., Sorensen, T. I., Lebrec, D., Burroughs, A. K., Morabito, A., Tine, F., Politi, F. and Traina, M. (1992) Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann. Intern. Med. 117, 59-70
111. D'Amico, G., Pagliaro, L. and Bosch, J. (1995) The treatment of portal hypertension: a meta-analytic review. Hepatology 22, 332-354
112. Villanueva, C., Minana, J., Ortiz, J., Gallego, A., Soriano, G., Torras, X., Sainz, S., Boadas, J., Cusso, X., Guarner, C. and Balanzo, J. (2001) Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N. Engl. J. Med. 345, 647-655
113. Groszmann, R. J., Garcia-Tsao, G., Bosch, J., Grace, N. D., Burroughs, A. K., Planas, R., Escorsell, A., Garcia-Pagan, J. C., Patch, D., Matloff, D. S. et al. (2005) β-Blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 353, 2254-2261
114. Tandon, P., Abraldes, J. G., Berzigotti, A., Garcia-Pagan, J. C. and Bosch, J. (2010) Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J. Hepatol. 53, 273-282
115. Guturu, P. and Shah, V. (2009) New insights into the pathobiology of portal hypertension. Hepatol. Res 39, 1016-1019
116. Gracia-Sancho, J., Lavina, B., Rodriguez-Vilarrupla, A., Garcia-Caldero, H., Bosch, J. and Garcia-Pagan, J. C. (2007) Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J. Hepatol. 47, 220-227
117. Angus, P.W. (2006) Role of endothelin in systemic and portal resistance in cirrhosis. Gut 55, 1230-1232
118. Gupta, T. K., Toruner, M., Chung, M. K. and Groszmann, R. J. (1998) Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28, 926-931
119. Schepke, M., Wiest, R., Flacke, S., Heller, J., Stoffel-Wagner, B., Herold, T., Ghauri, M. and Sauerbruch, T. (2008) Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. Am. J. Gastroenterol. 103, 1152-1158
120. Jalan, R. and Hayes, P. C. (2000) Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut 46, 527-533
121. Lee, F. Y., Albillos, A., Colombato, L. A. and Groszmann, R. J. (1992) The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 16, 1043-1048
122. Sieber, C. C., Lopez-Talavera, J. C. and Groszmann, R. J. (1993) Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 104, 1750-1754
123. Martin, P. Y., Xu, D. L., Niederberger, M., Weigert, A., Tsai, P., St John, J., Gines, P. and Schrier, R. W. (1996) Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am. J. Physiol. 270, F494-F499
124. Mathie, R. T., Ralevic, V., Moore, K. P. and Burnstock, G. (1996) Mesenteric vasodilator responses in cirrhotic rats: a role for nitric oxide? Hepatology 23, 130-136
125. Rolla, G., Brussino, L., Colagrande, P., Dutto, L., Polizzi, S., Scappaticci, E., Bergerone, S., Morello, M., Marzano, A., Martinasso, G. et al. (1997) Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 26, 842-847
126. Wiest, R., Shah, V., Sessa, W. C. and Groszmann, R. J. (1999) NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am. J. Physiol. 276, G1043-G1051
127. Tazi, K. A., Barriere, E., Moreau, R., Heller, J., Sogni, P., Pateron, D., Poirel, O. and Lebrec, D. (2002) Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 122, 1869-1877
128. Iwakiri, Y. (2007) The molecules: Mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J. Clin. Gastroenterol. 41, S288-S294
129. Tsai, M.-H., Iwakiri, Y., Cadelina, G., Sessa, W. C. and Groszmann, R. J. (2003) Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 125, 1452-1461
130. Abraldes, J. G., Iwakiri, Y., Loureiro-Silva, M., Haq, O., Sessa, W. C. and Groszmann, R. J. (2006) Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G980-G987
131. Heller, J., Schepke, M., Gehnen, N., Molderings, G. J., Muller, A., Erhard, J., Spengler, U. and Sauerbruch, T. (1999) Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 116, 387-393
132. Colle, I. O., De Vriese, A. S., Van Vlierberghe, H. R., Lameire, N. H. and De Vos, M. M. (2004) Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur. J. Gastroenterol. Hepatol. 16, 139-145
133. Hartleb, M., Moreau, R., Cailmail, S., Gaudin, C. and Lebrec, D. (1994) Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis. Gastroenterology 107, 1085-1093
134. Hennenberg, M., Biecker, E., Trebicka, J., Jochem, K., Zhou, Q., Schmidt, M., Jakobs, K. H., Sauerbruch, T. and Heller, J. (2006) Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 130, 838-854
135. Hennenberg, M., Trebicka, J., Kohistani, A. Z., Heller, J. and Sauerbruch, T. (2009) Vascular hyporesponsiveness to angiotensin II in rats with CCl4-induced liver cirrhosis. Eur. J. Clin. Invest. 39, 906-913
136. Iwakiri, Y., Cadelina, G., Sessa, W. C. and Groszmann, R. J. (2002) Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G1074-G1081
137. Bernardi, M. and Domenicali, M. (2005) The renin-angiotensin-aldosterone system in cirrhosis. In Ascites and Renal Dysfunction in Liver Disease (Gines, P., Arroyo, V., Rodes, J. and Schrier, R. W., eds.), pp. 43-53, Blackwell Publishing, Oxford
138. Castro, A., Jimenez, W., Claria, J., Ros, J., Martinez, J. M., Bosch, M., Arroyo, V., Piulats, J., Rivera, F. and Rodes, J. (1993) Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 18, 367-372
139. Schepke, M., Heller, J., Paschke, S., Thomas, J., Wolff, M., Neef, M., Malago, M., Molderings, G. J., Spengler, U. and Sauerbruch, T. (2001) Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: Evidence for a receptor-specific mechanism. Hepatology 34, 884-888
140. Murray, B. M. and Paller, M. S. (1985) Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action. Circ. Res. 57, 424-431
141. Helmy, A., Jalan, R., Newby, D. E., Hayes, P. C. and Webb, D. J. (2000) Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 118, 565-572
142. Sitzmann, J. V., Wu, Y. P., Aguilera, G., Cahill, P. A. and Burns, R. C. (1995) Loss of angiotensin-II receptors in portal hypertensive rabbits. Hepatology 22, 559-564
143. Hennenberg, M., Trebicka, J., Biecker, E., Schepke, M., Sauerbruch, T. and Heller, J. (2007) Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 45, 495-506
144. Osei, S. Y., Ahima, R. S., Minkes, R. K., Weaver, J. P., Khosla, M. C. and Kadowitz, P. J. (1993) Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur. J. Pharmacol. 234, 35-42
145. Ueda, S., Masumori-Maemoto, S., Ashino, K., Nagahara, T., Gotoh, E., Umemura, S. and Ishii, M. (2000) Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35, 998-1001
146. Oliveira, M. A., Fortes, Z. B., Santos, R. A., Kosla, M. C. and De Carvalho, M. H. (1999) Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 20, 1195-1201
147. Marangoni, R. A., Carmona, A. K., Passaglia, R. C., Nigro, D., Fortes, Z. B. and de Carvalho, M. H. (2006) Role of the kallikrein-kinin system in Ang-(1-7)-induced vasodilation in mesenteric arterioles ofWistar rats studied in vivo-in situ. Peptides 27, 1770-1775
148. Fernandes, L., Fortes, Z. B., Casarini, D. E., Nigro, D., Tostes, R. C. A., Santos, R. A. S. and de Carvalho, M. H. C. (2005) Role of PGI2 and effects of ACE inhibition on the bradykinin potentiation by angiotensin-(1-7) in resistance vessels of SHR. Regul. Pept. 127, 183-189
149. Fernandes, L., Fortes, Z. B., Nigro, D., Tostes, R. C. A., Santos, R. A. S. and Catelli de Carvalho, M. H. (2001) Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 37, 703-709
150. Schmaier, A. H. (2003) The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R1-13
151. Carvalho, M. B. L., Duarte, F. V., Faria-Silva, R., Fauler, B., Da Mata Machado, L. T., De Paula, R. D., Campagnole-Santos, M. J. and Santos, R. A. S. (2007) Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 50, 762-767
152. Vilas-Boas, W.W., Ribeiro-Oliveira, Jr, A., Pereira, R. M., Ribeiro, R. C., Almeida, J., Nadu, A. P., Simoes e Silva, A. C. and Santos, R. A. (2009) Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J. Gastroenterol. 15, 2512-2519
153. Santos, R. A. S., Brosnihan, K. B., Jacobsen, D.W., DiCorleto, P. E. and Ferrario, C. M. (1992) Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 19, 56-61
154. Epstein, M., Berk, D. P., Hollenberg, N. K., Adams, D. F., Chalmers, T. C., Abrams, H. L. and Merrill, J. P. (1970) Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am. J. Med. 49, 175-185
155. Çelebi, H., D̈onder, E. and Çeliker, H. (1997) Renal blood flow detection with Doppler ultrasonography in patients with hepatic cirrhosis. Arch. Intern. Med. 157, 564-566
156. Gines, A., Escorsell, A., Gines, P., Salo, J., Jimenez, W., Inglada, L., Navasa, M., Claria, J., Rimola, A., Arroyo, V. et al. (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105, 229-236
157. Ruiz-del-Arbol, L., Monescillo, A., Arocena, C., Valer, P., Gines, P., Moreira, V., Milicua, J. M., Jimenez, W. and Arroyo, V. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42, 439-447
158. Kramer, L. and Ḧorl, W. H. (2002) Hepatorenal syndrome. Semin. Nephrol. 22, 290-301
159. Laragh, J. H., Cannon, P. J., Bentzel, C. J., Sicinski, A. M. and Meltzer, J. I. (1963) Angiotensin II, norepinephrine, and renal transport of electrolytes and water in normal man and in cirrhosis with ascites. J. Clin. Invest. 42, 1179-1192
160. Bernardi, M., Trevisani, F., Gasbarrini, A. and Gasbarrini, G. (1994) Hepatorenal disorders: role of the reninangiotensin-aldosterone system. Semin. Liver Dis. 14, 23-34
161. Dharmani, M., Mustafa, M. R., Achike, F. I. and Sim, M. K. (2007) Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 561, 144-150
162. Van Der Wouden, E. A., Ochodnick', P., Van Dokkum, R. P., Roks, A. J., Deelman, L. E., De Zeeuw, D. and Henning, R. H. (2006) The role of angiotensin(1-7) in renal vasculature of the rat. J. Hypertens. 24, 1971-1978